The spinout’s technology was fundamental to Oxford’s covid vaccine, prompting OSI and Future Planet Capital to back a $168m round.

Vaccitech, a UK-based developer of vaccines for infectious diseases and cancer spun out of University of Oxford, closed a $168m series B round today backed by the institution’s venture fund Oxford Sciences Innovation.
Future Planet Capital, a venture capital firm focused on university startups and spinouts, also took part in the round, which was led by M&G Investment Management, a division of impact investment manager M&G.
Internet company Tencent, biopharmaceutical firm Gilead Sciences and the state-owned Monaco Constitutional…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Thierry Heles

Thierry Heles is the editor of Global University Venturing, host of the Beyond the Breakthrough interview podcast and responsible for the monthly GUV Gazette (sign up here for free).
email
Linked in